| 翻訳と辞書 |
| Bromelain (pharmacology) ： ウィキペディア英語版 |
Bromelain (pharmacology)
A concentrate of proteolytic enzymes from the pineapple plant enriched in bromelain is approved in Europe for the debridement (removal of eschar, that is dead and damaged tissue) of severe burn wounds under the trade name NexoBrid.〔(【引用サイトリンク】title=EPAR summary for the public: NexoBrid )〕 In the US, it has completed Phase III clinical trials and has the tentative trade name Debrase. It was developed by MediWound, Germany; and Teva is responsible for development and marketing in the US.〔(【引用サイトリンク】title=New Drugs Online Report for bromelain )〕
The medicine has been granted orphan drug status by the European Medicines Agency (EMA).
==Medical uses==
The medication is approved for burns of degrees IIb, i.e. deep partial skin thickness burns, to III, i.e. full thickness burns, and has been shown to significantly reduce the necessity of surgical debridement (15% versus 63% under standard treatment) and skin transplants (18% versus 34%) in a randomized controlled trial.〔
The concentrate is solved in a sterile gel basis, applied onto the burn wound, covered with a wound dressing, and removed after four hours. The healthy surrounding skin has to be protected with a sterile paraffin ointment. The EMA recommends that the treatment should only be used in hospitals with specialised burns centres.〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Bromelain (pharmacology)」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|